Martindale: The Complete Drug Reference

Provides unbiased and evaluated information on drugs and medicines in use around the world.

Martindale: The Complete Drug Reference is prepared by an experienced team of pharmacists and life scientists who use their professional expertise to select the most clinically relevant and appropriate information from reliable published sources. It provides an unbiased and evaluated digest of the literature.provides you with practical, evidence-based, global guidance, allowing you to quickly understand the characteristics of drugs and their clinical uses.

• Breadth : No other source has the breadth of coverage or level of detail making it the ideal first-line reference work as well as a trusted source of information for more detailed drug enquiries
• Global coverage : Martindale is the leading resource in terms of international coverage, with 43 countries covered – alternative publications have a narrow regional focus
• Objectivity : Respected for its accuracy of content and independence from pharmaceutical industry. Based on published information and extensively referenced
• International adoption : Recognised and adopted worldwide

• Over 6,300 drug monographs (and over 7,500 online, accessible via a subscription to MedicinesComplete)
• Over 185,000 preparations (and over 270,000 online, via MedicinesComplete)
• Over 54,000 reference citations
• Over 20,000 (and 28,000 online, via MedicinesComplete) manufacturers and distributors
• Proprietary preparations from 43 countries and regions
• Nearly 700 treatment reviews, with references from the published literature
• Information to help you identify medicines, the local equivalent and the manufacturer
• Herbals, diagnostic agents, radiopharmaceuticals, pharmaceutical excipients, toxins, and poisons as well as drugs and medicines

Further antivirals, including drugs active against HIV (bictegravir, dapivirine, doravirine, ibalizumab), smallpox (tecovirimat), cytomegalovirus (letermovir), influenza (baloxavir marboxil), and hepatitis C (glecaprevir, pibrentasvir, voxilaprevir)

• New treatment options for migraine (erenumab, fremanezumab, galcanezumab), narcolepsy (solriamfetol), hyperkalaemia (sodium zirconium cyclosilicate), postpartum depression (brexanolone), eosinophilic asthma (benralizumab), hypoactive sexual desire disorder (bremelanotide), glaucoma (netarsudil), African trypanosomiasis (fexinidazole), and irritable bowel syndrome (tenapanor)

• New antidiabetic drugs, including ertugliflozin, evogliptin, semaglutide, and sotagliflozin

• Further antineoplastics for treating cancers including PARP inhibitors (niraparib, rucaparib, talazoparib), PI3K inhibitors (alpelisib, copanlisib, duvelisib), and CAR-T therapies (axicabtagene ciloleucel, tisagenlecleucel)

• Novel targeted treatments for retinal dystrophy (voretigene neparvovec), neurotrophic keratitis (cenegermin), paroxysmal nocturnal haemoglobinuria (ravulizumab), hereditary transthyretin amyloidosis (inotersen, patisiran), spinal muscular atrophy (nusinersen), and hereditary angioedema (lanadelumab)

Updated coverage of proprietary preparations in 43 countries including Australia, China, UK, and the USA.